


AMENDMENTS TO THE CLAIMS

Claim 1. (currently amended) A peptide derivative represented by the general formula (I) or a salt thereof:



Wherein Z represents a furyl group ~~an aryl group which may or may not have a substituent or a heteroaryl group which may or may not have a substituent~~; n represents ~~0, 1 or 2~~; AA₁-AA₂ represents Lys-Val or Arg-Leu; and R represents -OH or -NH₂.

Claims 2-3. (cancelled)

Claim 4. (previously presented) A pharmaceutical composition comprising a peptide derivative or a salt thereof according to claim 1, and a pharmaceutically acceptable carrier thereof.

Claim 5. (original) The pharmaceutical composition according to claim 4, which is a PAR-2-activating agent.

Claims 6-7 (cancelled)

Claim 8 (currently amended) A method of treating a patient suffering from or susceptible to decrease of saliva secretion, ~~the decrease of lacrimal fluid secretion or~~ gastrointestinal disorder, comprising administering to the patient a peptide derivative or a salt thereof according to claim 1.

Claim 9. (currently amended) The method of claim 8 wherein a patient is identified as suffering from decrease of saliva secretion, ~~the decrease of lacrimal fluid secretion or~~ gastrointestinal disorder and the peptide derivative or a salt thereof is administered to the identified patient.

Claim 10. (currently amended) A method of treating a patient suffering from or susceptible to dysfunction of masticatory, dysphagia, dysgeusia (taste disorder), ozostomia, intra-oral cavity dysphoria, intra-oral cavity infection, intra-oral cavity inflammation, dry eye, ectocornea detachment, keratitis, corneal ulcer, conjunctivitis,

stomach ulcer, duodenal ulcer, gastritis, diarrhea, or enteritis ~~or Sjogren's syndrome~~,
comprising:

administering to the patient a peptide derivative or a salt thereof according to
claim 1.

Claim 11. (currently amended) The method of claim 10 wherein the patient is
identified as suffering from dysfunction of masticatory, dysphagia, dysgeusia (taste
disorder), ozostomia, intra-oral cavity dysphoria, intra-oral cavity infection, intra-oral
cavity inflammation, dry eye, ectocornea detachment, keratitis, corneal ulcer,
conjunctivitis, stomach ulcer, duodenal ulcer, gastritis, diarrhea, or enteritis ~~or Sjogren's
syndrome~~ and the peptide derivative or a salt thereof is administered to the identified
patient.